Professor of Medicine, University Tex Houston
Oncology
Dr. Vassiliki A. Papadimitrakopoulou, MD
|
|
Give Review
Doctor Vassiliki A. Papadimitrakopoulou, MD works in the field of Oncology. She received 1 awards: "Regional Top Doctor". Vassiliki Papadimitrakopoulou is a published doctor as well. She has 79 publications published. The latest was: Chemoprevention in head and neck cancer: basic science and clinical application. Vassiliki Papadimitrakopoulou accepts Medicare payments and is listed with Medicare.gov.
Publications
- Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations.
- Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in l...
- New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development.
- Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
- Ceritinib for the treatment of late-stage (metastatic) non-small cell lung Cancer.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung Cancer.
- Optimizing biomarkers and endpoints in oral Cancer chemoprevention trials.
- The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non-Small-Cell Lung Cancer: Focus on Clinical Tri...
- Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung Cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance.
- Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small-Cell Lung Cancer after Neoadjuvant C...
- Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non-Small-Cell Lung Cancer.
- Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design.
- Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant Gliomas.
- Carcinogenesis of head and neck Cancer and the role of chemoprevention in its reversal.
- Retinoids in head and neck chemoprevention.
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
- The Akt/mTOR and mitogen-activated protein kinase pathways in lung Cancer therapy.
- Phenotype and genotype of advanced preMalignant head and neck lesions after chemopreventive therapy.
- A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma.
- A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status.
- Primary parotid Lymphoma: the effect of International Prognostic Index on outcome.
- Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid Tumors.
- Combined-modality therapy in paranasal sinus Cancer.
- Chemoprevention in head and neck Cancer: basic science and clinical application.
- Cyclin D1 and Cancer development in laryngeal premalignancy patients.
- Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
- Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and Cancer development.
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome.
- Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell Lung canc...
- DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma.
- Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma.
- Fenretinide activity in retinoid-resistant Oral leukoplakia.
- Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck Cancer.
- Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung Cancer in vitro and in vivo.
- Induction of p53-regulated genes and tumor regression in lung Cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
- Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract Cancer.
- Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
- Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification.
- Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
- Epidermal growth factor receptor expression and gene copy number in the risk of oral Cancer.
- Biology of oral preMalignant lesions: concepts and implications for chemoprevention.
- [Biomarkers of carcinogenesis of the upper and lower airway epithelium and the role of chemoprevention].
- Molecular and cellular biomarkers for field Cancerization and multistep process in head and neck tumorigenesis.
- Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and ...
- Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral preMalignant lesions.
- Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell Cancer of the head and neck.
- Biochemoprevention for dysplastic lesions of the upper aerodigestive tract.
- Frequent inactivation of p16INK4a in oral preMalignant lesions.
- Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck Cancer: the M.D. Anderson Cancer Center experience.
- Low-dose isotretinoin versus beta-carotene to prevent Oral carcinogenesis: long-term follow-up.
- Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung Cancer.
- Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patie...
- The future of NSCLC: molecular profiles guiding treatment decisions.
- Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.
- Gene expression profiling predicts the development of oral Cancer.
- Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
- Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy.
- High-dose fenretinide in Oral leukoplakia.
- Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in Oral premalignancy.
- Pilot randomized phase II study of celecoxib in oral preMalignant lesions.
- Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and n...
- Postoperative radiotherapy for maxillary sinus Cancer: long-term outcomes and toxicities of treatment.
- Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung Cancer.
- Akt activation correlates with adverse outcome in tongue Cancer.
- Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract preMalignant lesions.
- The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell Lung carcinoma: potential for decreased toxicity an...
- The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis.
- Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis.
- Focus on head and neck Cancer.
- Effects of amifostine on Acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
- Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an Oral rinse in oropharyngeal leukoplakia.
- Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
- An attenuated adenovirus, ONYX-015, as mouthwash therapy for preMalignant oral dysplasia.
- Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung Cancer.
- Dose-dense therapy with a novel irinotecan regimen for small-cell lung Cancer.
- Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract Cancer.
- Scientific Advances in Lung Cancer 2015.
Schools
University Of Pat Med School
Columbia Presbyterian Med Center
University Of Texas M D Anderson Cancer Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Texas Health Science Center -
New York Presbyterian Hospital - Columbia Campus -
St Luke's-Roosevelt Hospital Center
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1144311101 | |
| NPPES Provider LastName | PAPADIMITRAKOPOULOU | |
| NPPES Provider FirstName | VASSILIKI | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 236.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 31.0 | |
| Percent Opioid Claims | 13.14 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1144311101 |
| Last Name Of The Provider | PAPADIMITRAKOPOULOU |
| First Name Of The Provider | VASSILIKI |
| View All |
Similar Doctors
|
|
Dr. Paolo Anderlini, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristy L. Richards, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry J. Conter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Hui, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abenaa M. Brewster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas Mitsiades, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Abdul-Masih F P. Farha, MD |
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|